Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paolo Pronzato

Showing results (71-80 of 95) with videos related to

Pageof 10
Sort By:
Expert Opinion on Biological Therapy|August 22, 2022
Immunotherapy-chemotherapy combinations for non-small cell lung cancer: current trends and future perspectivesEugenia Cella, Lodovica Zullo, Silvia Marconi, et al.
Journal of the National Cancer Institute|September 17, 2011
Concurrent vs sequential adjuvant chemotherapy and hormone therapy in breast cancer: a multicenter randomized phase III trialDavide Bedognetti, Mario Roberto Sertoli, Paolo Pronzato, et al.
JAMA|January 1, 2016
Ovarian Suppression With Triptorelin During Adjuvant Breast Cancer Chemotherapy and Long-term Ovarian Function, Pregnancies, and Disease-Free Survival: A Randomized Clinical TrialMatteo Lambertini, Luca Boni, Andrea Michelotti, et al.
Future Oncology (London, England)|December 19, 2019
Endocrine therapy for hormone receptor-positive, HER2-negative metastatic breast cancer: extending endocrine sensitivityAntonio Frassoldati, Laura Biganzoli, Roberto Bordonaro, et al.
JCO Oncology Practice|December 20, 2019
Use of Electronic Administrative Databases to Measure Quality Indicators of Breast Cancer Care: Experience of Five Regional Oncology Networks in ItalyValentina Guarneri, Paolo Pronzato, Oscar Bertetto, et al.
Cancers|May 6, 2020
Precision Medicine for NSCLC in the Era of Immunotherapy: New Biomarkers to Select the Most Suitable Treatment or the Most Suitable PatientGiovanni Rossi, Alessandro Russo, Marco Tagliamento, et al.
Journal of the National Cancer Institute|December 1, 2021
Long-Term Outcomes With Pharmacological Ovarian Suppression During Chemotherapy in Premenopausal Early Breast Cancer PatientsMatteo Lambertini, Luca Boni, Andrea Michelotti, et al.
JAMA|July 21, 2011
Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trialLucia Del Mastro, Luca Boni, Andrea Michelotti, et al.
Bioorganic & Medicinal Chemistry|March 30, 2010
Novel 2-[(benzylamino)methyl]pyrrolidine-3,4-diol derivatives as alpha-mannosidase inhibitors and with antitumor activities against hematological and solid malignanciesClaudia Bello, Michele Cea, Giovanna Dal Bello, et al.
The Lancet. Oncology|July 17, 2023
Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 studyReinhard Dummer, Paola Queirolo, Pauline Gerard Duhard, et al.
Pageof 10

Showing results (71-80 of 95) with videos related to

Sort By:
Pageof 10
Expert Opinion on Biological Therapy|August 22, 2022
Immunotherapy-chemotherapy combinations for non-small cell lung cancer: current trends and future perspectivesEugenia Cella, Lodovica Zullo, Silvia Marconi, et al.
Journal of the National Cancer Institute|September 17, 2011
Concurrent vs sequential adjuvant chemotherapy and hormone therapy in breast cancer: a multicenter randomized phase III trialDavide Bedognetti, Mario Roberto Sertoli, Paolo Pronzato, et al.
JAMA|January 1, 2016
Ovarian Suppression With Triptorelin During Adjuvant Breast Cancer Chemotherapy and Long-term Ovarian Function, Pregnancies, and Disease-Free Survival: A Randomized Clinical TrialMatteo Lambertini, Luca Boni, Andrea Michelotti, et al.
Future Oncology (London, England)|December 19, 2019
Endocrine therapy for hormone receptor-positive, HER2-negative metastatic breast cancer: extending endocrine sensitivityAntonio Frassoldati, Laura Biganzoli, Roberto Bordonaro, et al.
JCO Oncology Practice|December 20, 2019
Use of Electronic Administrative Databases to Measure Quality Indicators of Breast Cancer Care: Experience of Five Regional Oncology Networks in ItalyValentina Guarneri, Paolo Pronzato, Oscar Bertetto, et al.
Cancers|May 6, 2020
Precision Medicine for NSCLC in the Era of Immunotherapy: New Biomarkers to Select the Most Suitable Treatment or the Most Suitable PatientGiovanni Rossi, Alessandro Russo, Marco Tagliamento, et al.
Journal of the National Cancer Institute|December 1, 2021
Long-Term Outcomes With Pharmacological Ovarian Suppression During Chemotherapy in Premenopausal Early Breast Cancer PatientsMatteo Lambertini, Luca Boni, Andrea Michelotti, et al.
JAMA|July 21, 2011
Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trialLucia Del Mastro, Luca Boni, Andrea Michelotti, et al.
Bioorganic & Medicinal Chemistry|March 30, 2010
Novel 2-[(benzylamino)methyl]pyrrolidine-3,4-diol derivatives as alpha-mannosidase inhibitors and with antitumor activities against hematological and solid malignanciesClaudia Bello, Michele Cea, Giovanna Dal Bello, et al.
The Lancet. Oncology|July 17, 2023
Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 studyReinhard Dummer, Paola Queirolo, Pauline Gerard Duhard, et al.
Pageof 10